CervoMed Q3 2026 net loss narrows to $5.9 million from $7.7 million
CervoMed reported a third-quarter 2026 net loss of approximately $5.9 million, down from $7.7 million a year earlier, as research and development spending fell and grant revenue ended. Cash, cash equivalents, and marketable securities were approximately $19.6 million at September 30, 2026, and the company says this will fund planned operations through the third quarter of 2027. The filing also reiterates that a strategic partner is needed to advance neflamapimod into Phase 3 for dementia with Lewy bodies, and the company's forward-looking statements cite the risk of not being able to continue as a going concern.
Key points
- Net loss was approximately $5.9 million for the three months ended September 30, 2026, versus $7.7 million for the same period in 2025.
- No grant revenue was recognized in the quarter, compared with approximately $0.3 million a year earlier, because no further funding is available under the $21.3 million National Institute on Aging grant.
- R&D expenses fell to approximately $3.7 million from $6.0 million, while G&A expenses rose to approximately $2.4 million from $2.3 million.
- Cash and marketable securities were approximately $19.6 million at September 30, 2026, down from $20.9 million at December 31, 2025.
The filing
Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.